Acute Myeloid Leukemia Clinical Trial
— AML-AZAOfficial title:
A Randomized, Multi-center Phase II Trial to Assess the Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
The primary purpose of the study is to determine, whether the addition of 5-azacytidine to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).
Status | Completed |
Enrollment | 214 |
Est. completion date | December 2012 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 61 Years and older |
Eligibility |
Inclusion Criteria: - Patients with newly diagnosed AML (except APL) according to the FAB or WHO classification, including AML evolving from MDS or other hematological diseases and AML after previous cytotoxic therapy or radiation (secondary AML). - Bone marrow aspirate or biopsy must contain = 20% blasts of all nucleated cells or differential blood count must contain = 20% blasts. In AML FAB M6 = 30% of non-erythroid cells in the bone marrow must be leukemic blasts. In AML defined by cytogenetic aberrations the proportion of blasts may be < 20%. - Age = 61 years - Informed consent, personally signed and dated to participate in the study - Male patients enrolled in this trial must use adequate barrier birth control measures during the course of the 5-azacytidine treatment and for at least 3 months after the last administration of 5-azacytidine. Exclusion Criteria: - Patients who are not eligible for standard chemotherapy as described in chapter 5.2 and 5.3 - Hyperleukocytosis (leukocytes > 20,000/µl) at study entry. These patients should be treated with hydroxyurea or receive leukocytapheresis treatment (if leukocytes > 100,000/µl) according to routine practice and entered into the study when leukocyte counts below 20,000/µl are reached. This applies only for the controlled part of the study. - Patients with initial hyperleukocytosis above 20,000/µl can only be enrolled into the controlled part of the study, but not in the run-in dose finding part. - Known central nervous system manifestation of AML - Cardiac Disease: Heart failure NYHA class 3 or 4; unstable coronary artery disease (MI more than 6 months prior to study entry is permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) - Chronically impaired renal function (creatinin clearance < 30 ml / min) - Inadequate liver function (ALT and AST = 2.5 x ULN) if not caused by leukemic infiltration - Total bilirubin = 1.5 x ULN if not caused by leukemic infiltration - Known HIV and/or hepatitis C infection - Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy - Evidence or recent history of CNS disease, including primary or metastatic brain tumors, seizure disorders - Uncontrolled active infection - Concurrent malignancies other than AML with an estimated life expectancy of less than two years - History of organ allograft - Hypersensitivity to cytarabine (not including drug fever or exanthema), daunorubicin, azacytidine or mannitol - Previous treatment of AML except hydroxyurea and up to 2 days of =100 mg/m2/d cytarabine - Previous therapy with 5-azacytidine (i.e. for an antecedent myelodysplastic syndrome) - Patients with investigational drug therapy outside of this trial during or within 4 weeks of study entry should be discussed with the study office whether study participation is possible - Any severe concomitant condition, which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | RWTH Aachen, Medizinische Klinik IV | Aachen | |
Germany | Sozialstiftung Bamberg, Klinikum am Bruderwald, Med. Klinik V | Bamberg | |
Germany | Klinikum Bayreuth, Medizinische Klinik IV | Bayreuth | |
Germany | Charite Campus Benjamin Franklin, Universitätsmedizin Berlin, Medizinische Klinik III | Berlin | |
Germany | Städt. Kliniken Bielefeld gem. GmbH, Klinikum Mitte, Klinik für Hämatologie, Onkologie, Palliativmedizin | Bielefeld | |
Germany | Klinikum Chemnitz, Krankenhaus Küchenwald, Klinik für Innere Medizin III | Chemnitz | |
Germany | Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I | Dresden | |
Germany | Katholische Krankenhaus Duisburg | Duisburg | |
Germany | Universitätsklinikum Erlangen, Medizinische Klinik 5 | Erlangen | |
Germany | Universitätsklinikum Essen, Klinik für Hämatologie | Essen | |
Germany | Klinikum Frankfurt (Oder) GmbH | Frankfurt (Oder) | |
Germany | Klinikum der Johann Wolfgang Goethe-Universität Frakfurt am Main | Frankfurt am Main | |
Germany | Asklepios Klinik St. Georg, Hämatologische Abteilung | Hamburg | |
Germany | St. Bernward Krankenhaus Hildesheim, Medizinische Klinik II | Hildesheim | |
Germany | Westpfalz-Klinikum GmbH, Med. Klinik I | Kaiserslautern | |
Germany | Stiftungsklinikum Mittelrhein, Hämatologie/ Onkologie | Koblenz | |
Germany | Johannes Gutenberg-Universität Mainz Klinikum, III. Medizinische Klinik und Poliklinik | Mainz | |
Germany | Phillips Universität Marburg, Fachbereich 20, ZIM | Marburg | |
Germany | Klinikum rechts der Isar, III. Medizinische Klinik | Muenchen | |
Germany | Universitätsklinikum Münster, Medizinische Klinik und Poliklinik A | Münster | |
Germany | Klinikum Nürnberg, Medizinische Klinik 5 | Nurnberg | |
Germany | Klinikum Osnabrück, Klinik für Onkologie, Hämatologie, Immunologie | Osnabruck | |
Germany | Klinikum der Universität Regensburg, Klinik und Poliklinik für Innere Medizin I | Regensburg | |
Germany | Robert-Bosch-Krankenhaus, Zentrum für Innere Medizin | Stuttgart | |
Germany | Klinikum Mutterhaus der Borromäerinnen, Innere Medizin I | Trier | |
Germany | Dr. Horst-Schmidt-Kliniken | Wiesbaden | |
Germany | Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II | Wurzburg |
Lead Sponsor | Collaborator |
---|---|
University Hospital Muenster | Amgen, Celgene Corporation |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Median Event Free Survival (EFS) of all AML patients | continously up to 12 months after start of study | No | |
Secondary | Median event free survival of AML patients with different cytogenetic and molecular risk groups | continously up to 12 months after study start | No | |
Secondary | Median overall survival of all AML patients | continously up to 12 month after start of study | No | |
Secondary | Median overall survival of AML patients with different cytogenetic and molecular risk groups | continously up to 12 month after start of study | No | |
Secondary | Relapse free survival | continously up to 12 months after start of study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |